Latanoprostene bunod

Last updated

Latanoprostene bunod
Latanoprostene bunod.svg
Clinical data
Trade names Vyzulta
Other namesBOL-303259-X
AHFS/Drugs.com Monograph
License data
Drug class Prostaglandin analog
ATC code
Legal status
Legal status
Identifiers
  • 4-Nitrooxybutyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.251.571 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C27H41NO8
Molar mass 507.624 g·mol−1
3D model (JSmol)
  • C1[C@H]([C@@H]([C@H]([C@H]1O)C/C=C\CCCC(=O)OCCCCO[N+](=O)[O-])CC[C@H](CCC2=CC=CC=C2)O)O
  • InChI=1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1
  • Key:LOVMMUBRQUFEAH-UIEAZXIASA-N

Latanoprostene bunod, sold under the brand name Vyzulta, is an ophthalmic medication used for the reduction of intraocular pressure in people with open-angle glaucoma or ocular hypertension. [2] [3] It is a prostaglandin analog [2] which, when broken down by esterases and other metabolism, produces latanoprost acid and eventually nitrous oxide. Latanoprost increases uveoscleral outflow while the nitrous oxide increases outflow via the trabecular meshwork. [3]

Contents

The most common side effects include conjunctival (eye) redness, eye irritation, and eye discomfort (pain). [4] Latanoprostene bunod may cause the iris (colored part of the eye) to become darker in color. [4]

Latanoprostene bunod was approved for medical use in the United States in November 2017. [2] [4] [5]

Medical uses

Latanoprostene bunod is indicated for the reduction of intraocular pressure in people with open-angle glaucoma or ocular hypertension. [2]

History

The US Food and Drug Administration (FDA) approved latanoprostene bunod based on evidence from two clinical trials that enrolled 840 participants with open angle glaucoma or ocular hypertension. [4] The trials evaluated the benefits and side effects of latanoprostene bunod. [4] In each trial, participants were randomly assigned to receive either latanoprostene bunod or an approved drug timolol (ophthalmic solution) every day for three months. [4] Neither the participants nor the health care providers knew which treatment was being given until after the trials were completed. [4] The trials were conducted in the United States, the United Kingdom, Germany, Italy, Bulgaria, the Czech Republic, and Japan. [4]

References

  1. ↑ "Regulatory Decision Summary for Vyzulta". Health Canada. 27 December 2018.
  2. 1 2 3 4 5 "Vyzulta- latanoprostene bunod solution/ drops". DailyMed. 1 May 2019. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
  3. 1 2 Hoy SM (May 2018). "Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension". Drugs. 78 (7): 773–780. doi: 10.1007/s40265-018-0914-6 . PMC   5976683 . PMID   29761382.
  4. 1 2 3 4 5 6 7 8 "Vyzulta". U.S. Food and Drug Administration (FDA). 2 November 2017. Archived from the original on 11 July 2024. Retrieved 11 July 2024.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  5. ↑ "Bausch + Lomb And Nicox Announce FDA Approval Of Vyzulta (Latanoprostene Bunod Ophthalmic Solution), 0.024%" (Press release). Valeant Pharmaceuticals. 2 November 2017. Archived from the original on 11 July 2024. Retrieved 11 July 2024– via PR Newswire.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.